LOUISVILLE, Colo., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will participate in three upcoming investor conferences:
Craig-Hallum 15th Annual Alpha Select Conference
1x1 Meetings
Date: Tuesday, November 19, 2024
Location: New York, NY
Wolfe Research Healthcare Conference 2024
1x1 Meetings
Date: Wednesday, November 20, 2024
Location: New York, NY
Canaccord Genuity Medtech, Diagnostics and Digital Health & Services Forum
Presentation and 1x1 Meetings
Presentation Date and Time: Thursday, November 21, 2024 at 1:00 PM ET
Location: New York, NY
The presentation will be webcast live and available for replay under “News & Events” in the Investors section of the Company's website at biodesix.com.
About Biodesix
Biodesix is a leading diagnostic solutions company with five Medicare-covered tests available for patients with lung diseases. The blood-based Nodify Lung® Nodule Risk Assessment, consisting of the Nodify XL2® and the Nodify CDT® tests, evaluates the risk of malignancy in pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. The blood-based IQLung™ test portfolio for lung cancer patients integrates the GeneStrat® targeted ddPCR™ test, the GeneStrat NGS® test, and the VeriStrat® test to support treatment decisions across all stages of lung cancer and expedite personalized treatment. In addition, Biodesix collaborates with the world’s leading biopharmaceutical companies to provide biomarker discovery, diagnostic test development, and clinical trial support services. For more information, visit biodesix.com.
Note: Biodesix, Nodify Lung, IQLung, GeneStrat, GeneStrat NGS, VeriStrat, Nodify XL2 and Nodify CDT are trademarks or registered trademarks of Biodesix, Inc. ddPCR is a trademark of Bio-Rad Laboratories, Inc.
Contacts:
Media:
Natalie St. Denis
This email address is being protected from spambots. You need JavaScript enabled to view it.
1-720-925-9285
Investors:
Chris Brinzey
This email address is being protected from spambots. You need JavaScript enabled to view it.
1-339-970-2843
Last Trade: | US$1.70 |
Daily Change: | 0.04 2.41 |
Daily Volume: | 132,814 |
Market Cap: | US$246.810M |
October 07, 2024 September 05, 2024 August 07, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB